Harvard Apparatus adjusted EBITDA rises 11% year over year to $1.7 million; revenue increases 11% to $22.7 million in 2Q26
HRGN•Second-quarter results
Harvard Apparatus Regenerative Technology posted 2Q26 revenue of $22.7 million, up 11% year-over-year.
GAAP diluted loss per share widened to $(0.64); adjusted diluted loss per share widened to $(0.14).
Adjusted EBITDA rose 11% to $1.7 million; adjusted gross margin fell 0.5 percentage points to 56.7%.
Cash flow, debt and outlook
Net debt increased to $33.5 million as of June 30, 2026; year-to-date cash flow from operations was $(0.3) million.
The company raised its FY26 revenue growth outlook to 3%–5%. Third-quarter 2026 guidance calls for revenue of $21.0 million-$22.6 million.
